Connect with us

Health

Targeted therapy achieves excellent outcomes, reduces side effects in high-risk Hodgkin lymphoma – News-Medical.Net

Scientists are reporting results of the first frontline clinical trial to use targeted therapy to treat high-risk pediatric Hodgkin lymphoma.

Published

on

Article feature image

Brentuximab vedotin is an anti-CD30 antibody drug conjugate. The drug, which is already approved to treat adults with Hodgkin lymphoma, is targeted specifically to Hodgkin Reed Sternberg cells (cancer cells in Hodgkin lymphoma). Brentuximab vedotin delivers the medicine directly where it is needed.
“I think of brentuximab vedotin as a smart drug,” said first and corresponding author Monika Metzger, M.D., St. Jude Departments of Oncology and Global Pediatric Medicine. “Unlike conventional chemotherapy,…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
Royal Perth Hospital staff in quarantine after COVID safety breach – WAtoday
Oxford Starts First Study to Reinfect Recovered Covid Patients – Bloomberg